FC
ADMA icon

Financial Consulate’s ADMA Biologics ADMA Stock Holding History

Financial Consulate’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293 Sell
35
-2,965
-99% -$27K ﹤0.01% 1395
2026
Q1 		$27K Hold
3,000
– – ﹤0.01% 433
2025
Q4 		$54.7K Hold
3,000
– – 0.01% 303
2025
Q3 		$44K Buy
+3,000
New +$51.4K 0.01% 329

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Financial Consulate's ADMA Position: Q2 2026 in Review

Financial Consulate reduced its ADMA Biologics (ADMA) stake by 99% in Q2 2026, selling an estimated $27K and leaving 35 shares worth $293. The position accounts for ﹤0.01% of the portfolio, ranked #1395.

Financial Consulate first reported a position in ADMA in Q3 2025 and has held it in 4 quarters since. The position peaked at $54.7K in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Financial Consulate held 35 shares of ADMA Biologics worth $293 as of Q2 2026.
  • Financial Consulate sold 2,965 ADMA Biologics shares in Q2 2026, an estimated $27K.
  • ADMA Biologics made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #1395 holding.
  • Financial Consulate first reported a position in ADMA Biologics in Q3 2025 and has held it in 4 quarters since.
  • Financial Consulate's ADMA Biologics position peaked at $54.7K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.